Public disclosure of the August exercise status for stock options (19th issue with exercise price adjustment provisions). For the target month, 2,090,000 shares were issued, 20,900 options were exercised, accounting for 8.7% of the total issued shares. Unexercised options at month-end were 138,700, and the exercise restriction ratio was 2.2%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4883","jir_company_name":"Modulus (Modulus Therapeutics) Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4883-20260901-01.pdf","jir_short_summary":"Public disclosure of the August exercise status for stock options (19th issue with exercise price adjustment provisions). For the target month, 2,090,000 shares were issued, 20,900 options were exercised, accounting for 8.7% of the total issued shares. Unexercised options at month-end were 138,700, and the exercise restriction ratio was 2.2%.","jir_summary":"### Section Heading\nThis is a monthly exercise status notice for the 19th issue of stock acquisition rights issued to third parties. For the target month, 2,090,000 shares were issued, 20,900 stock options were actually exercised, representing 8.7% of the issued total. Unexercised rights at the end of the previous month were 159,600, and at month-end were 138,700, with an exercise ratio of 2.2% out of nine levels of compliance with exercise restrictions. This references the previously disclosed notice (as of May 27, 2026).\n\n### Section 2 Heading\nThe monthly trend shows a reduction in unexercised rights, while an 8.7% exercise rate is observed, and exercise restrictions in accordance with the regulations continue to be observed. The status of issued shares and treasury shares, and future exercise trends, may influence the market. For details, please refer to the May 27 notice, and if there are additional disclosures, they will be announced as appropriate.","jir_financial_highlights":"Number of shares issued during the target month: 2,090,000 shares\nNumber of stock options exercised during the target month: 20,900 shares (Exercise rate 8.7% of total issued)\nUnexercised stock options (as of the end of the previous month): 159,600 shares\nUnexercised stock options (as of month-end): 138,700 shares\nExercise restriction status (exercise rate): 2.2% ","jir_category":"","jir_hashtags":"#ModulusStockOptions, #ShareRelatedInfo","jir_key_figures":"Issued shares: 2,090,000 shares\nNumber of stock options exercised: 20,900 shares\nTotal issued shares: 240,000 shares\nUnexercised stock options (month-end): 138,700 shares\nExercise ratio: 2.2%","jir_meta_title":"Modulus Therapeutics Co., Ltd. - Monthly Exercise Status of Stock Acquisition Rights (Third-Party Allocation) | August 2026","jir_meta_description":"Modulus Therapeutics reports the August monthly exercise status for the 19th issue of stock acquisition rights. Issued shares: 2,090,000; Exercised: 20,900; Unexercised: 138,700; Exercise restriction: 2.2%. See notices for details.","jir_og_title":"Modulus Therapeutics - Monthly Exercise Status of Stock Acquisition Rights | August 2026","jir_og_description":"Modulus Therapeutics announces the August exercise status for the 19th stock option. Issued: 2,090,000 shares; Exercised: 20,900; Unexercised: 138,700; Exercise restriction: 2.2%.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60005,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"stock_option","footnotes":""},"sector":[],"importance":[],"class_list":["post-109568","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n